We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

By LabMedica International staff writers
Posted on 12 Nov 2024

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related deaths. Now, a new study has found that a blood biomarker could serve as a promising clinical tool in antibiotic stewardship for sepsis management.

The study, conducted by scientists at the University of Uppsala (Uppsala, Sweden), aimed to assess the kinetics of four biomarkers in plasma from patients admitted to the ICU, including those with sepsis, and during antibiotic treatment. The study included 277 ICU patients, of whom 30% had sepsis, with the rest categorized as miscellaneous, other medical conditions, or trauma patients. Antibiotic treatment was either initiated or adjusted upon ICU admission. Plasma samples were collected at ICU admission and on days 2 and 3 of follow-up. The biomarkers studied were HBP (Heparin-binding protein), HNL Dimer (Human Neutrophil Lipocalin), HNL Total, and PCT (Procalcitonin). The data was compared to clinical scores like SOFA and KDIGO, as well as patient survival rates.

The study findings published in the journal PLOS ONE show that plasma levels of all four biomarkers were significantly elevated, with the highest concentrations observed in sepsis patients. Over the follow-up period, HNL Dimer levels decreased by day 2 and continued to drop by day 3 (p<0.00001), while the other three biomarkers remained unchanged. HNL Total demonstrated the strongest correlation with the clinical scores (p<0.0001) and was independently associated with these scores based on multiple regression analysis. These findings confirm their earlier research suggesting that HNL Dimer could be a valuable tool for antibiotic stewardship in sepsis, with HNL Total offering insight into epithelial cell activity and serving as a potential biomarker for managing organ failure in sepsis patients. 

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Silver Member
ACTH Assay
ACTH ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.